Pfizer’s Monthly Weight-Loss Shot Shows Wegovy-Like Side Effects in Mid-Stage Trial
NVO•Pfizer’s investigational monthly weight-loss shot produced gastrointestinal adverse events at rates comparable to Novo Nordisk’s Wegovy in a mid-stage Phase II trial. The therapy’s safety profile could heighten competitive pressure on Wegovy’s obesity market share during its next growth phase.
1. Mid-Stage Trial Findings
Pfizer’s monthly injectable weight-loss candidate entered a Phase II study enrolling several hundred participants with obesity and reported gastrointestinal side effects—including nausea and diarrhea—at incidence levels similar to those observed with Novo Nordisk’s weekly Wegovy regimen.
2. Competitive Implications
The emerging safety profile positions Pfizer as a direct competitor to Wegovy, potentially influencing physician prescribing and payer negotiations as both companies advance toward late-stage trials and eventual market launches.
